Daiichi Sankyo Company: Q1 FY 2026 revenue up 21% YoY, forecast raised on strong oncology sales and yen weaknessQuartr·1 day ago, 12:35 PMDSNKY-11.46%4568
Daiichi Sankyo Q1 FY26 operating profit falls 12% to JPY 85.1 billion; revenue rises 21.1% to JPY 574.7 billionPUBT·1 day ago, 03:30 AMDSNKY-11.46%4568
Daiichi Sankyo, AstraZeneca Datroway wins EU approval for first-line metastatic TNBC in non-immunotherapy patientsPUBT·1 day ago, 01:30 AMAZN-0.99%DSNKY-11.46%
Daiichi Sankyo Company: Oncology-driven revenue growth and FX gains lifted results, but profit fell on higher costsQuartr·1 day ago, 11:02 PMDSNKY-11.46%4568
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy | AZN Stock NewsStockTitan·2 days ago, 05:30 PMAZN-0.99%DSNKY-11.46%
Toyota Stock, SoftBank And Daiichi Sankyo Offer Reliable Japan Dividend IncomeSimplywall·Jul 27 at 10:13 AMTM-1.28%DSNKY-11.46%
Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY) Short Interest Up 1,183.6% in JulyMarket Beat·Jul 24 at 06:00 PMDSNKY-11.46%4568
Daiichi Sankyo’s Enhertu plus pertuzumab wins EU CHMP backing for first-line HER2+ metastatic breast cancerPUBT·Jul 24 at 06:01 AMDSNKY-11.46%4568
Canon Stock And 2 Japanese Dividend Stocks Offering Steady IncomeSimplywall·Jul 18 at 12:02 AM4568SFTBY+0.20%
Key facts: Wainua fails CV trial; Enhertu nears UK price dealTradingView·Jul 9 at 02:14 AMAZNAZN-0.99%
AstraZeneca Nears Enhertu Deal After 300 Million UK InvestmentGuruFocus·Jul 8 at 01:46 PMAZN-0.99%AZN
AstraZeneca Advances Rare Bone Disease Pipeline While Enhertu Expands In Europebenzinga_article·Jun 29 at 11:59 AMAZNAZN-0.99%
